Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-06-06FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the methylphenidate transdermal system (methylphenidate) submitted by PADAGIS US LLC.
-
FDA approval · 2013-06-04FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride CD (methylphenidate hydrochloride) from Lannett Company, Inc. unde…
-
CLINICAL_TRIALS trial_result · 2013-05-29Clinical Trial Update: A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 3]
A Phase 3 long-term study evaluating a medication for adults with ADHD has completed and results have been posted.
-
FDA approval · 2013-05-29FDA Approved: DEXTROAMPHETAMINE — Original Application (Cranbury Pharmaceuticals, LLC)
FDA approves Cranbury Pharmaceuticals' original ANDA for dextroamphetamine, a generic stimulant indicated for attention-deficit/hyperactivit…
-
CLINICAL_TRIALS trial_result · 2013-05-24Clinical Trial Update: Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia [Phase 4]
Phase 4 clinical trial evaluating ramelteon for ADHD-related sleep onset insomnia in adults has completed. Results were posted in 2013.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-05-21Clinical Trial Update: Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood [NA]
This completed clinical trial evaluated whether adding group-based behavioral therapy to stimulant medication benefits children with attenti…
-
FDA approval · 2013-05-20FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Strattera (atomoxetine hydrochloride) from Eli Lilly and Company, likely resulting in changes to…
-
FDA approval · 2013-05-15FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
FDA approved a supplemental application for QUILLIVANT XR, indicating a modification or addition to the existing NDA for this methylphenidat…
-
FDA approval · 2013-05-09FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the methylphenidate transdermal system, submitted by PADAGIS US LLC.
-
CLINICAL_TRIALS trial_result · 2013-05-07Clinical Trial Update: Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children [Phase 2, Phase 3]
Phase 2 and Phase 3 trials evaluating methylphenidate for children with autism spectrum disorder and attention-deficit/hyperactivity disorde…
-
FDA approval · 2013-05-06FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate submitted by Sandoz Inc under NDA 021284, marking an additional approval for the…
-
FDA approval · 2013-05-06FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride CD from Lannett Company, Inc., authorizing its marketing as a …
-
FDA approval · 2013-05-03FDA Approved: CONCERTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for CONCERTA (methylphenidate hydrochloride) submitted by Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2013-05-03Clinical Trial Update: Neurofeedback Intervention on the Development of ADHD in Children at Risk [NA]
A completed clinical trial assessing neurofeedback as an intervention affecting the development of ADHD in at-risk children. The study spons…
-
CLINICAL_TRIALS trial_result · 2013-05-03Clinical Trial Update: Effect of Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder [NA]
Completed clinical trial from the University of Ulm evaluating long-chain polyunsaturated fatty acids for effects on behavior and cognition …
-
CLINICAL_TRIALS trial_result · 2013-04-30Clinical Trial Update: Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD) [Phase 2]
Phase 2 trial results for TC-5619 in adults with inattentive-predominant ADHD report safety and efficacy data. The study was conducted by Ta…
-
CLINICAL_TRIALS withdrawal · 2013-04-23Clinical Trial Update: Parent-Provider Intervention for Improving Medication Adherence in Children With Attention Deficit Hyperactivity Disorder [NA]
A clinical trial evaluating a parent-provider intervention to improve medication adherence in children with ADHD has been withdrawn.
-
CLINICAL_TRIALS research · 2013-04-19Clinical Trial Update: Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder [NA]
The clinical trial evaluating organizational skills training for children with attention-deficit/hyperactivity disorder has completed its st…
-
CLINICAL_TRIALS trial_result · 2013-04-10Clinical Trial Update: Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia [Phase 3]
Phase 3 trial evaluating the safety and efficacy of eszopiclone in children and adolescents with ADHD-associated insomnia completed; results…
-
FDA approval · 2013-03-12FDA Approved: DURACLON — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for DURACLON (clonidine hydrochloride) from Mylan Institutional LLC.
-
FDA approval · 2013-03-08FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a generic combination of amphetamine salts (dextroamphetamine saccharat…
-
CLINICAL_TRIALS research · 2013-03-08Clinical Trial Update: Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
This completed clinical trial investigated the association between attention-deficit/hyperactivity disorder and bulimia nervosa in outpatien…
-
CLINICAL_TRIALS research · 2013-03-08Clinical Trial Update: Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy [NA]
A clinical trial update indicating completion of a study assessing EEG-neurofeedback therapy for attention-deficit/hyperactivity disorder.
-
CLINICAL_TRIALS withdrawal · 2013-03-05Clinical Trial Update: Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD [Phase 4]
This Phase 4 study evaluating atomoxetine for ADHD in adolescents and young adults with substance use disorder has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2013-03-04Clinical Trial Update: A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]
This clinical trial update reports completion of a Phase 2 study evaluating three dose levels of JNJ-31001074 for adults with Attention-Defi…